$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000106282213000030 Filed on August 01, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$238.0K	$214.0K	$199.0K
YoY Change	-36.02%	7.54%	-64.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.700M	$4.700M	$5.100M
YoY Change	6.82%	-7.84%	-5.56%
% of Gross Profit
Research & Development	$25.40M	$23.69M	$19.36M
YoY Change	32.35%	22.41%	-3.92%
% of Gross Profit
Depreciation & Amortization	$600.0K	$800.0K	$1.100M
YoY Change	-45.45%	-27.27%	-15.38%
% of Gross Profit
Operating Expenses	$31.45M	$28.84M	$25.68M
YoY Change	6.87%	12.3%	-3.03%
Operating Profit	-$31.22M	-$28.62M	-$25.48M
YoY Change	7.42%	12.34%	-1.72%
Interest Expense	$492.0K	$496.0K	$530.0K
YoY Change	-6.64%	-6.42%	-34.57%
% of Operating Profit
Other Income/Expense, Net	$11.00K	-$4.000K	$21.00K
YoY Change	175.0%	-119.05%	-30.0%
Pretax Income	-$31.70M	-$29.10M	-$25.90M
YoY Change	7.46%	12.36%	-2.63%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$31.66M	-$29.08M	-$25.93M
YoY Change	7.17%	12.14%	-2.65%
Net Earnings / Revenue	-13301.68%	-13588.79%	-13030.65%
Basic Earnings Per Share
Diluted Earnings Per Share	-$432.5K	-$397.0K	-$377.0K
COMMON SHARES
Basic Shares Outstanding	513.5M shares	513.0M shares	480.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$150.8M	$174.9M	$231.1M
YoY Change	-26.94%	-24.32%	40.57%
Cash & Equivalents	$19.58M	$23.25M	$33.78M
Short-Term Investments	$131.2M	$151.7M	$197.3M
Other Short-Term Assets	$7.257M	$6.684M	$6.582M
YoY Change	-19.4%	1.55%	69.9%
Inventory
Prepaid Expenses
Receivables	$895.0K	$1.014M	$182.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$159.4M	$183.1M	$238.3M
YoY Change	-26.25%	-23.17%	40.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.84M	$42.15M	$44.53M
YoY Change	-3.85%	-5.33%	-7.95%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$53.56M	$53.56M	$53.56M
YoY Change	0.0%	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$158.0K	$65.00K	$157.0K
YoY Change	17.04%	-58.6%	-37.94%
Total Long-Term Assets	$140.1M	$140.3M	$142.8M
YoY Change	-1.17%	-1.73%	-2.69%
TOTAL ASSETS
Total Short-Term Assets	$159.4M	$183.1M	$238.3M
Total Long-Term Assets	$140.1M	$140.3M	$142.8M
Total Assets	$299.5M	$323.4M	$381.1M
YoY Change	-16.31%	-15.13%	20.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.709M	$6.281M	$4.579M
YoY Change	125.48%	37.17%	24.73%
Accrued Expenses	$11.53M	$11.32M	$15.05M
YoY Change	-9.8%	-24.75%	87.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.675M	$22.68M	$1.510M
YoY Change	8.63%	1401.85%	9.42%
Total Short-Term Liabilities	$23.60M	$40.90M	$21.56M
YoY Change	23.87%	89.76%	62.97%
LONG-TERM LIABILITIES
Long-Term Debt	$20.61M	$0.00	$22.68M
YoY Change	-7.52%	-100.0%	-6.24%
Other Long-Term Liabilities	$37.39M	$35.26M	$59.28M
YoY Change	20.28%	-40.52%	15.42%
Total Long-Term Liabilities	$58.00M	$35.26M	$81.95M
YoY Change	8.68%	-56.98%	8.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.60M	$40.90M	$21.56M
Total Long-Term Liabilities	$58.00M	$35.26M	$81.95M
Total Liabilities	$113.7M	$108.3M	$136.2M
YoY Change	8.25%	-20.46%	11.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$986.5M	-$954.9M	-$845.4M
YoY Change	12.75%	12.95%	15.86%
Common Stock	$514.0K	$514.0K	$481.0K
YoY Change	3.84%	6.86%	42.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.503M	$1.503M	$630.0K
YoY Change	138.57%	138.57%	82.61%
Treasury Stock Shares	814.0K shares	814.0K shares	380.0K shares
Shareholders Equity	$185.7M	$215.1M	$244.9M
YoY Change
Total Liabilities & Shareholders Equity	$299.5M	$323.4M	$381.1M
YoY Change	-16.31%	-15.13%	20.62%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$31.66M	-$29.08M	-$25.93M
YoY Change	7.17%	12.14%	-2.65%
Depreciation, Depletion And Amortization	$600.0K	$800.0K	$1.100M
YoY Change	-45.45%	-27.27%	-15.38%
Cash From Operating Activities	-$23.90M	-$21.10M	-$22.00M
YoY Change	-4.4%	-4.09%	-7.17%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$400.0K	-$100.0K
YoY Change	200.0%	300.0%	-66.67%
Acquisitions
YoY Change
Other Investing Activities	$20.50M	$10.90M	$26.90M
YoY Change	75.21%	-59.48%	0.37%
Cash From Investing Activities	$20.30M	$10.40M	$26.90M
YoY Change	75.0%	-61.34%	1.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-300.0K	-200.0K
YoY Change	-100.0%	50.0%	-92.31%
NET CHANGE
Cash From Operating Activities	-23.90M	-21.10M	-22.00M
Cash From Investing Activities	20.30M	10.40M	26.90M
Cash From Financing Activities	0.000	-300.0K	-200.0K
Net Change In Cash	-3.600M	-11.00M	4.700M
YoY Change	-72.09%	-334.04%	2250.0%
FREE CASH FLOW
Cash From Operating Activities	-$23.90M	-$21.10M	-$22.00M
Capital Expenditures	-$300.0K	-$400.0K	-$100.0K
Free Cash Flow	-$23.60M	-$20.70M	-$21.90M
YoY Change	-5.22%	-5.48%	-6.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Paid Net InterestPaidNet	1029000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4000000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7661000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6281000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1378000	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1014000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8922000	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11321000	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81034000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	83416000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	23000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	31000	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1170928000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1166605000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3313000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3978000	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1600000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2013Q2	us-gaap	Assets Assets	323393000	USD
CY2012Q4	us-gaap	Assets Assets	371778000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	230935000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	183076000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30423000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23254000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33779000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186309000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7169000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-152530000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	514000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	512000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25894000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55840000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55046000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29091000	USD
	us-gaap	Contracts Revenue ContractsRevenue	495000	USD
	us-gaap	Contracts Revenue ContractsRevenue	351000	USD
CY2012Q2	us-gaap	Contracts Revenue ContractsRevenue	199000	USD
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	211000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	128000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	623000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13910000	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13405000	USD
CY2013Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2219000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1618000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1741000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	4243000	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	31661000	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	59276000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29920000	USD
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	55033000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8993000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4669000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8727000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4162000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2013Q2	us-gaap	Goodwill Goodwill	44543000	USD
CY2013Q2	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	5100000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	317000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2251000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-364000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-168000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	48000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	44000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-335000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2834000	USD
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
	us-gaap	Interest Expense InterestExpense	1067000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	530000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	496000	USD
	us-gaap	Interest Expense InterestExpense	1002000	USD
	us-gaap	Interest Paid Net InterestPaidNet	962000	USD
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	58000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	97000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	371778000	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	44000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	105100000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	108309000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	323393000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	114000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18285000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	40903000	USD
CY2013Q2	us-gaap	Licenses Revenue LicensesRevenue	3000	USD
	us-gaap	Licenses Revenue LicensesRevenue	79000	USD
	us-gaap	Licenses Revenue LicensesRevenue	148000	USD
CY2012Q2	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1574000	USD
CY2013Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	22678000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21877000	USD
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
CY2014Q2	us-gaap	Mortgage Loans On Real Estate Periodic Payment Terms Balloon Payment Amount MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentAmount	21400000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1299000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-851000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-102720000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39533000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45403000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48959000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55054000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-25931000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-29080000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55799000	USD
	us-gaap	Operating Expenses OperatingExpenses	55362000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	25679000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	28838000	USD
	us-gaap	Operating Expenses OperatingExpenses	54753000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54179000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54863000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-25480000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-28624000	USD
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	6684000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6349000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	109000	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	65000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	37000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-41000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-11000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32283000	USD
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	35256000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17000	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	873000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	285000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	80954000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	151776000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	329000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1238000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	347000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	276000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-136000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	49384000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	121623000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	102000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42152000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42634000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	706000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	773000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23692000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44019000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19355000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42392000	USD
CY2012Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2013Q2	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-954886000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-899832000	USD
CY2012Q2	us-gaap	Revenues Revenues	199000	USD
CY2013Q2	us-gaap	Revenues Revenues	214000	USD
	us-gaap	Revenues Revenues	574000	USD
	us-gaap	Revenues Revenues	499000	USD
CY2013Q2	us-gaap	Secured Debt SecuredDebt	22700000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3313000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3978000	USD
CY2013Q2	us-gaap	Short Term Investments ShortTermInvestments	152124000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	192785000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	276000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	347000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	215084000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	266678000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	266678000	USD
CY2012Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	244896000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	297568000	USD
CY2013Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	215084000	USD
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	380000	shares
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	814000	shares
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1503000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	630000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	285000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	873000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	8000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-41000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	480479000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	512757000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	480634000	shares
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	7650622	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	513083000	shares
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	4243000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1741000	USD
CY2012Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2162000	USD
CY2013Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	477000	USD
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	80808	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue	1.98
CY2013Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	847000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1361000	USD
CY2012Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	680000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1626000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2352000	USD
CY2013Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1022000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1952000	USD
CY2012Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	915000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	13237519	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	513453422	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-13-000030-index-headers.html	Edgar Link	pending
0001062822-13-000030-index.html	Edgar Link	pending
0001062822-13-000030.txt	Edgar Link	pending
0001062822-13-000030-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
lxrx-20130630.xml	Edgar Link	completed
lxrx-20130630.xsd	Edgar Link	pending
lxrx-20130630_cal.xml	Edgar Link	unprocessable
lxrx-20130630_def.xml	Edgar Link	unprocessable
lxrx-20130630_lab.xml	Edgar Link	unprocessable
lxrx-20130630_pre.xml	Edgar Link	unprocessable
lxrx630201310-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2013 Q3 Form 10-Q Financial Statement

#000106282213000030 Filed on August 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2013 Q3 Form 10-Q Financial Statement

#000106282213000030 Filed on August 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx